In Vivo Selection of Streptococcus pneumoniae, Resistant to Quinolones, Including Sparfloxin.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Clinical Microbiology and Infection

• Publication date

  1995-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/J.1469-0691.1995.TB00027.XPMID 11866724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epidémiologie de la résistance aux antibiotiques de Streptococcus pneumoniae en France. Réseau national de surveillance (1984–1993)

  1994cited by this paper
• Induction of resistance of Streptococcus pneumoniae to quinolones in vitro.

  1993cited by this paper
• Comparative in vitro activities of sparfloxacin (CI-978; AT-4140) and other antimicrobial agents against staphylococci, enterococci, and respiratory tract pathogens

  1990cited by this paper
• Pneumococcal resistance to antibiotics

  1990cited by this paper
• In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent.

  1990cited by this paper

• Global Transcriptome Analysis of the Responses of a Fluoroquinolone-Resistant Streptococcus pneumoniae Mutant and Its Parent to Ciprofloxacin

  2006cites this paper
• New Mutation in ParE in a Pneumococcal In Vitro Mutant Resistant to Fluoroquinolones

  2001cites this paper
• Genetic Analyses of Mutations Contributing to Fluoroquinolone Resistance in Clinical Isolates ofStreptococcus pneumoniae

  2001cites this paper
• Activities of Clinafloxacin, Gatifloxacin, Gemifloxacin, and Trovafloxacin against Recent Clinical Isolates of Levofloxacin-Resistant Streptococcus pneumoniae

  2000cites this paper
• Mouse Pneumococcal Pneumonia Models

  1999cites this paper
• Activities of Newer Fluoroquinolones against Streptococcus pneumoniae Clinical Isolates Including Those with Mutations in the gyrA, parC, and parELoci

  1999cites this paper
• Relationship between mutations in parC and gyrA of clinical isolates of Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin.

  1999cites this paper
• Relationship between of clinical isolates of mutations in parC and gyrA Streptococcus pneumoniae and resistance to ciprofloxacin and grepafloxacin

  1999cites this paper
• Activities of New Fluoroquinolones against Fluoroquinolone-Resistant Pathogens of the Lower Respiratory Tract

  1998cites this paper
• Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy.

  1998cites this paper
• Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae

  1997cites this paper
• Non-gyrA-mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae.

  1997cites this paper
• Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae

  1997cites this paper
• and in vitro . of Streptococcus pneumoniae obtained in vivo mutantsgenes to fluoroquinolone resistance of Contribution of mutations in gyrA and parC

  1996cites this paper
• High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA

  1996cites this paper
• Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro

  1996cites this paper